Pharmacyclics (PCYC) Tops Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pharmacyclics (PCYC) Remains Rated Sector Perform at RBC, PT Raised to $145
February 19, 2015 9:04 AM ESTRBC Capital maintained a Sector Perform rating on Pharmacyclics (NASDAQ: PCYC) and raised its price target to $145.00 (from $130.00). Comments follow Q4 results. Analyst Michael J. Yee thinks bulls are in control of the stock.
"We predict stock likely to keep trending up... More
Nomura Securities Upgrades Pharmacyclics (PCYC) to Buy
February 19, 2015 6:59 AM ESTNomura Securities upgraded Pharmacyclics (NASDAQ: PCYC) from Neutral to Buy with a price target of $196.00 (from $195.00), saying the RESONATE-2 data is key to upside in 2015
Analyst M. Ian Somaiya commented, "Pharmacyclics management reaffirmed their 2015 US sales guidance of $1bn and more importantly confirmed results of... More
UPDATE: Roth Capital Cuts Pharmacyclics (PCYC) to Neutral; Sees FY15 Guidance, Market Expectations Priced into Shares
February 19, 2015 6:56 AM EST(Updated - February 19, 2015 8:59 AM EST)
Roth Capital cuts Pharmacyclics (Nasdaq: PCYC) from Buy to Neutral and moves its price target from $189 to $187 following FY14 results reported on Wednesday night.
After markets close, Pharmacyclics posted Q4 EPS of $0.96 on revs of $290... More
JPMorgan Downgrades Pharmacyclics (PCYC) to Neutral
February 19, 2015 6:55 AM ESTJPMorgan downgraded Pharmacyclics (NASDAQ: PCYC) from Overweight to Neutral with a price target of $173.00 (from $152.00).
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $170.21 yesterday.
... More